Richard Wilson
Beatson West of Scotland Cancer Centre
Publications 6
PURPOSEOutcomes in RAS-mutant metastatic colorectal cancer (mCRC) remain poor and patients have limited therapeutic options. Adavosertib is the first small-molecule inhibitor of WEE1 kinase. We hyp...
1 CitationsSource
#1Richard Adams (Velindre NHS Trust)H-Index: 30
#2David FisherH-Index: 23
Last. Philip Quirke (University of Leeds)H-Index: 101
view all 21 authors...
PURPOSEDespite extensive randomized evidence supporting the use of treatment breaks in metastatic colorectal cancer (mCRC), they are not universally offered to patients despite improvements in qual...
#1Richard Adams (Cardiff University)H-Index: 30
#2David Fisher (UCL: University College London)H-Index: 23
Last. R. Butler (UoB: University of Bristol)
view all 16 authors...
#1Janet Graham (Beatson West of Scotland Cancer Centre)H-Index: 17
#2Louise Brown (UCL: University College London)H-Index: 14
Last. T MaughanH-Index: 5
view all 6 authors...
#1Catherine Hanna (Glas.: University of Glasgow)H-Index: 7
#2Kathleen A Boyd (Glas.: University of Glasgow)H-Index: 14
Last. Richard Wilson (Beatson West of Scotland Cancer Centre)
view all 0 authors...
Introduction null Over half of the 1.5 million individuals globally who are diagnosed with colorectal cancer (CRC) present with stage II-III disease. Understanding clinician attitudes towards treatment for this group is paramount to contextualise real-world outcomes and plan future trials. The aim of this study was to assess clinician awareness of trials assessing the optimal duration of CRC adjuvant therapy, their attitudes towards shorter treatment and their self-reported practice. null Method...